Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RVMD
stocks logo

RVMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.579
+40.94%
--
--
-1.572
+39.13%
--
--
-1.622
+23.83%
Estimates Revision
The market is revising Downward the revenue expectations for Revolution Medicines, Inc. (RVMD) for FY2025, with the revenue forecasts being adjusted by -24.96% over the past three months. During the same period, the stock price has changed by 69.54%.
Revenue Estimates for FY2025
Revise Downward
down Image
-24.96%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.44%
In Past 3 Month
Stock Price
Go Up
up Image
+69.54%
In Past 3 Month
Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 79.95 USD with a low forecast of 67.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 79.95 USD with a low forecast of 67.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 78.920
sliders
Low
67.00
Averages
79.95
High
104.00
Current: 78.920
sliders
Low
67.00
Averages
79.95
High
104.00
Wolfe Research
initiated
$75
2025-11-17
Reason
Wolfe Research
Price Target
$75
2025-11-17
initiated
Reason
Wolfe Research initiated coverage of Revolution Medicines with an Outperform rating and $75 price target. Revolution is "emerging as the clear leader in pancreatic cancer" with darxonrasib, the analyst tells investors. First-in-class is important in this space and the firm's analysis suggests the key second-line Phase 3 readout will hit next year, the analyst added.
JPMorgan
Brian Cheng
upgrade
$71 -> $82
2025-11-06
Reason
JPMorgan
Brian Cheng
Price Target
$71 -> $82
2025-11-06
upgrade
Reason
JPMorgan analyst Brian Cheng raised the firm's price target on Revolution Medicines to $82 from $71 and keeps an Overweight rating on the shares. JPMorgan also added the shares to its Analyst Focus List as a growth idea. While the company's Q3 report seems like a "non-event," it is making strategic moves to position the entire portfolio to "win in the long run,: the analyst tells investors in a research note.
H.C. Wainwright
Robert Burns
Buy
maintain
$72 -> $73
2025-11-06
Reason
H.C. Wainwright
Robert Burns
Price Target
$72 -> $73
2025-11-06
maintain
Buy
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Revolution Medicines to $73 from $72 and keeps a Buy rating on the shares following the Q3 report. The firm says new clinical data support the thesis that elironrasib addresses resistance mechanisms to first-generation KRAS inhibitors.
RBC Capital
Leonid Timashev
Outperform
initiated
$77
2025-11-03
Reason
RBC Capital
Leonid Timashev
Price Target
$77
2025-11-03
initiated
Outperform
Reason
RBC Capital analyst Leonid Timashev initiated coverage of Revolution Medicines with an Outperform rating and $77 price target. The firm believes Revolution is best positioned to execute on targeting RAS across oncology, given its "impressive" efficacy data, development lead, and pipeline. RBC thinks the company's Phase III readout in 2026 is "highly likely to hit."
Mizuho
Joseph Catanzaro
Outperform
initiated
$90
2025-10-20
Reason
Mizuho
Joseph Catanzaro
Price Target
$90
2025-10-20
initiated
Outperform
Reason
Mizuho analyst Joseph Catanzaro initiated coverage of Revolution Medicines with an Outperform rating and $90 price target. The firm believes the company's portfolio of RAS(ON) inhibitors are positioned to play "significant roles" in pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. Daraxonrasib in PDAC alone can drive "meaningful upside" in the shares, the analyst tells investors in a research note. Mizuho believes Revolution's portfolio could generate $10B in risk-adjusted sales in 2035.
Raymond James
Strong Buy
maintain
$72 -> $76
2025-10-17
Reason
Raymond James
Price Target
$72 -> $76
2025-10-17
maintain
Strong Buy
Reason
Raymond James raised the firm's price target on Revolution Medicines to $76 from $72 and keeps a Strong Buy rating on the shares. RevMed's daraxonrasib has been included in the FDA's Commisioner's National Priority Review Voucher program aimed at "Reducing downstream health care utilization, addressing a public health crisis, boosting domestic manufacturing, or increasing medication affordability with Most Favored Nation pricing," the analyst tells investors in a research note. The inclusion should truncate the time for daraxonrasib to reach the market in 2L RASmut pancreatic cancer, the firm says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Revolution Medicines Inc (RVMD.O) is -11.71, compared to its 5-year average forward P/E of -9.40. For a more detailed relative valuation and DCF analysis to assess Revolution Medicines Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.40
Current PE
-11.71
Overvalued PE
-5.91
Undervalued PE
-12.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.80
Undervalued EV/EBITDA
-9.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2420.47
Current PS
0.00
Overvalued PS
8044.80
Undervalued PS
-3203.86
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 843.78% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 843.78% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RVMD News & Events

Events Timeline

(ET)
2025-11-05
16:20:10
Revolution Medicines reaffirms GAAP net loss forecast for FY25
select
2025-11-05
16:19:02
Revolution Medicines Announces Q3 EPS of $1.61, Exceeding Consensus Estimate of $1.41
select
2025-10-27 (ET)
2025-10-27
08:11:53
Revolution Medicines reveals that the U.S. FDA has awarded ODD to daraxonrasib.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
12-12NASDAQ.COM
ETF Outflow Warning: XBI, EXAS, RVMD, RNA

  • 52-Week Range of XBI: XBI's share price has a 52-week low of $66.66 and a high of $125.87, with the last trade recorded at $123.35.

  • Understanding ETFs: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), impacting their underlying holdings.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.

[object Object]
Preview
3.0
12-11MarketWatch
Eight Stock Selections to Capitalize on a Robust Sector of the Market

  • Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.

  • Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.

[object Object]
Preview
4.5
12-03NASDAQ.COM
Significant ETF Inflows: XBI, EXAS, RVMD, RNA

  • 52-Week Range of XBI: XBI's share price has a 52-week low of $66.66 and a high of $123.47, with the last trade recorded at $120.40.

  • 200-Day Moving Average: The article suggests that comparing the current share price to the 200-day moving average can be a useful technical analysis tool.

  • ETFs Trading Mechanism: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Impact of Inflows and Outflows: Monitoring week-over-week changes in shares outstanding helps identify ETFs with significant inflows or outflows, which can affect the underlying holdings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Revolution Medicines Inc (RVMD) stock price today?

The current price of RVMD is 78.92 USD — it has increased 0.52 % in the last trading day.

arrow icon

What is Revolution Medicines Inc (RVMD)'s business?

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

arrow icon

What is the price predicton of RVMD Stock?

Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 79.95 USD with a low forecast of 67.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Revolution Medicines Inc (RVMD)'s revenue for the last quarter?

Revolution Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Revolution Medicines Inc (RVMD)'s earnings per share (EPS) for the last quarter?

Revolution Medicines Inc. EPS for the last quarter amounts to -1.61 USD, increased 71.28 % YoY.

arrow icon

What changes have occurred in the market's expectations for Revolution Medicines Inc (RVMD)'s fundamentals?

The market is revising Downward the revenue expectations for Revolution Medicines, Inc. (RVMD) for FY2025, with the revenue forecasts being adjusted by -24.96% over the past three months. During the same period, the stock price has changed by 69.54%.
arrow icon

How many employees does Revolution Medicines Inc (RVMD). have?

Revolution Medicines Inc (RVMD) has 534 emplpoyees as of December 13 2025.

arrow icon

What is Revolution Medicines Inc (RVMD) market cap?

Today RVMD has the market capitalization of 15.26B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free